Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 203

1.

A cryptic imatinib-sensitive G3BP1-PDGFRB rearrangement in a myeloid neoplasm with eosinophilia.

Jan M, Grinshpun DE, Villalba JA, Dal Cin P, Sykes DB, Iafrate AJ, Ebert BL, Hobbs GS, Nardi V.

Blood Adv. 2020 Feb 11;4(3):445-448. doi: 10.1182/bloodadvances.2019001182. No abstract available.

2.

Rapid and deep-scale ubiquitylation profiling for biology and translational research.

Udeshi ND, Mani DC, Satpathy S, Fereshetian S, Gasser JA, Svinkina T, Olive ME, Ebert BL, Mertins P, Carr SA.

Nat Commun. 2020 Jan 17;11(1):359. doi: 10.1038/s41467-019-14175-1.

3.

Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.

Kurppa KJ, Liu Y, To C, Zhang T, Fan M, Vajdi A, Knelson EH, Xie Y, Lim K, Cejas P, Portell A, Lizotte PH, Ficarro SB, Li S, Chen T, Haikala HM, Wang H, Bahcall M, Gao Y, Shalhout S, Boettcher S, Shin BH, Thai T, Wilkens MK, Tillgren ML, Mushajiang M, Xu M, Choi J, Bertram AA, Ebert BL, Beroukhim R, Bandopadhayay P, Awad MM, Gokhale PC, Kirschmeier PT, Marto JA, Camargo FD, Haq R, Paweletz CP, Wong KK, Barbie DA, Long HW, Gray NS, Jänne PA.

Cancer Cell. 2020 Jan 13;37(1):104-122.e12. doi: 10.1016/j.ccell.2019.12.006.

PMID:
31935369
4.

Clonal hematopoiesis as a model for premalignant changes during aging.

Steensma DP, Ebert BL.

Exp Hematol. 2019 Dec 12. pii: S0301-472X(19)31133-6. doi: 10.1016/j.exphem.2019.12.001. [Epub ahead of print]

PMID:
31838005
5.

Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy.

Garcia JS, Bhatt S, Fell G, Sperling AS, Burgess M, Keshishian H, Yilma B, Brunner A, Neuberg D, Carr SA, Ebert BL, Ballen K, Stone RM, DeAngelo DJ, Medeiros BC, Letai A.

Am J Hematol. 2020 Mar;95(3):245-250. doi: 10.1002/ajh.25692. Epub 2019 Dec 22.

PMID:
31804723
6.

Non-del(5q) myelodysplastic syndromes-associated loci detected by SNP-array genome-wide association meta-analysis.

McGraw KL, Cheng CH, Chen YA, Hou HA, Nilsson B, Genovese G, Cluzeau T, Pellagatti A, Przychodzen BP, Mallo M, Arenillas L, Mohamedali A, Adès L, Sallman DA, Padron E, Sokol L, Moreilhon C, Raynaud S, Tien HF, Boultwood J, Ebert BL, Sole F, Fenaux P, Mufti GJ, Maciejewski JP, Kanetsky PA, List AF.

Blood Adv. 2019 Nov 26;3(22):3579-3589. doi: 10.1182/bloodadvances.2019000922.

7.

Myelodysplastic syndromes (MDS) occurring in Agent Orange exposed individuals carry a mutational spectrum similar to that of de novo MDS.

Sperling AS, Leventhal M, Gibson CJ, Ebert BL, Steensma DP.

Leuk Lymphoma. 2020 Mar;61(3):728-731. doi: 10.1080/10428194.2019.1689394. Epub 2019 Nov 12. No abstract available.

PMID:
31714164
8.

Clonal hematopoiesis in human aging and disease.

Jaiswal S, Ebert BL.

Science. 2019 Nov 1;366(6465). pii: eaan4673. doi: 10.1126/science.aan4673. Review.

PMID:
31672865
9.

Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence.

Nazha A, Sekeres MA, Bejar R, Rauh MJ, Othus M, Komrokji RS, Barnard J, Hilton CB, Kerr CM, Steensma DP, DeZern A, Roboz G, Garcia-Manero G, Erba H, Ebert BL, Maciejewski JP.

JCO Precis Oncol. 2019;3. doi: 10.1200/po.19.00119. Epub 2019 Sep 20.

10.

A new opening on aortic stenosis: predicting prognosis with clonal haematopoiesis.

Lin AE, Libby P, Ebert BL.

Eur Heart J. 2020 Feb 21;41(8):940-942. doi: 10.1093/eurheartj/ehz752. No abstract available.

PMID:
31634387
11.

Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1).

Meyer T, Jahn N, Lindner S, Röhner L, Dolnik A, Weber D, Scheffold A, Köpff S, Paschka P, Gaidzik VI, Heckl D, Wiese S, Ebert BL, Döhner H, Bullinger L, Döhner K, Krönke J.

Leukemia. 2020 Feb;34(2):404-415. doi: 10.1038/s41375-019-0578-6. Epub 2019 Oct 1.

PMID:
31576005
12.

CHIPing Away at Breast Cancer.

Sperling AS, Ebert BL.

J Natl Cancer Inst. 2020 Jan 1;112(1):10-11. doi: 10.1093/jnci/djz158. No abstract available.

PMID:
31504659
13.

A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies.

Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, Giacomelli AO, Wong W, Kim J, Chao S, Kurppa KJ, Yang X, Milenkowic K, Piccioni F, Root DE, Rücker FG, Flamand Y, Neuberg D, Lindsley RC, Jänne PA, Hahn WC, Jacks T, Döhner H, Armstrong SA, Ebert BL.

Science. 2019 Aug 9;365(6453):599-604. doi: 10.1126/science.aax3649.

PMID:
31395785
14.

Clonal Hematopoiesis: Crossroads of Aging, Cardiovascular Disease, and Cancer: JACC Review Topic of the Week.

Libby P, Sidlow R, Lin AE, Gupta D, Jones LW, Moslehi J, Zeiher A, Jaiswal S, Schulz C, Blankstein R, Bolton KL, Steensma D, Levine RL, Ebert BL.

J Am Coll Cardiol. 2019 Jul 30;74(4):567-577. doi: 10.1016/j.jacc.2019.06.007. Review.

PMID:
31345432
15.

Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation.

Jan M, Leventhal MJ, Morgan EA, Wengrod JC, Nag A, Drinan SD, Wollison BM, Ducar MD, Thorner AR, Leppanen S, Baronas J, Stevens J, Lane WJ, Kekre N, Ho VT, Koreth J, Cutler CS, Nikiforow S, Alyea EP 3rd, Antin JH, Soiffer RJ, Ritz J, Lindsley RC, Ebert BL.

Blood Adv. 2019 Jul 23;3(14):2199-2204. doi: 10.1182/bloodadvances.2019000445.

16.

CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice.

DeZern AE, Malcovati L, Ebert BL.

Am Soc Clin Oncol Educ Book. 2019 Jan;39:400-410. doi: 10.1200/EDBK_239083. Epub 2019 May 17. Review.

17.

Gene-centric functional dissection of human genetic variation uncovers regulators of hematopoiesis.

Nandakumar SK, McFarland SK, Mateyka LM, Lareau CA, Ulirsch JC, Ludwig LS, Agarwal G, Engreitz JM, Przychodzen B, McConkey M, Cowley GS, Doench JG, Maciejewski JP, Ebert BL, Root DE, Sankaran VG.

Elife. 2019 May 9;8. pii: e44080. doi: 10.7554/eLife.44080.

18.

Patterns of substrate affinity, competition, and degradation kinetics underlie biological activity of thalidomide analogs.

Sperling AS, Burgess M, Keshishian H, Gasser JA, Bhatt S, Jan M, Słabicki M, Sellar RS, Fink EC, Miller PG, Liddicoat BJ, Sievers QL, Sharma R, Adams DN, Olesinski EA, Fulciniti M, Udeshi ND, Kuhn E, Letai A, Munshi NC, Carr SA, Ebert BL.

Blood. 2019 Jul 11;134(2):160-170. doi: 10.1182/blood.2019000789. Epub 2019 May 1.

PMID:
31043423
19.

Engineered Bcor mutations lead to acute leukemia of progenitor B-1 lymphocyte origin in a sensitized background.

Yin M, Chung YJ, Lindsley RC, Walker RL, Zhu YJ, Ebert BL, Meltzer PS, Aplan PD.

Blood. 2019 Jun 13;133(24):2610-2614. doi: 10.1182/blood.2018864173. Epub 2019 Apr 16.

PMID:
30992267
20.

Intergenerational epigenetic inheritance of cancer susceptibility in mammals.

Lesch BJ, Tothova Z, Morgan EA, Liao Z, Bronson RT, Ebert BL, Page DC.

Elife. 2019 Apr 9;8. pii: e39380. doi: 10.7554/eLife.39380.

21.

Genomic subtyping and therapeutic targeting of acute erythroleukemia.

Iacobucci I, Wen J, Meggendorfer M, Choi JK, Shi L, Pounds SB, Carmichael CL, Masih KE, Morris SM, Lindsley RC, Janke LJ, Alexander TB, Song G, Qu C, Li Y, Payne-Turner D, Tomizawa D, Kiyokawa N, Valentine M, Valentine V, Basso G, Locatelli F, Enemark EJ, Kham SKY, Yeoh AEJ, Ma X, Zhou X, Sioson E, Rusch M, Ries RE, Stieglitz E, Hunger SP, Wei AH, To LB, Lewis ID, D'Andrea RJ, Kile BT, Brown AL, Scott HS, Hahn CN, Marlton P, Pei D, Cheng C, Loh ML, Ebert BL, Meshinchi S, Haferlach T, Mullighan CG.

Nat Genet. 2019 Apr;51(4):694-704. doi: 10.1038/s41588-019-0375-1. Epub 2019 Mar 29.

22.

Impaired human hematopoiesis due to a cryptic intronic GATA1 splicing mutation.

Abdulhay NJ, Fiorini C, Verboon JM, Ludwig LS, Ulirsch JC, Zieger B, Lareau CA, Mi X, Roy A, Obeng EA, Erlacher M, Gupta N, Gabriel SB, Ebert BL, Niemeyer CM, Khoriaty RN, Ancliff P, Gazda HT, Wlodarski MW, Sankaran VG.

J Exp Med. 2019 May 6;216(5):1050-1060. doi: 10.1084/jem.20181625. Epub 2019 Mar 26.

23.

Stabilization of the Max Homodimer with a Small Molecule Attenuates Myc-Driven Transcription.

Struntz NB, Chen A, Deutzmann A, Wilson RM, Stefan E, Evans HL, Ramirez MA, Liang T, Caballero F, Wildschut MHE, Neel DV, Freeman DB, Pop MS, McConkey M, Muller S, Curtin BH, Tseng H, Frombach KR, Butty VL, Levine SS, Feau C, Elmiligy S, Hong JA, Lewis TA, Vetere A, Clemons PA, Malstrom SE, Ebert BL, Lin CY, Felsher DW, Koehler AN.

Cell Chem Biol. 2019 May 16;26(5):711-723.e14. doi: 10.1016/j.chembiol.2019.02.009. Epub 2019 Mar 14.

PMID:
30880155
24.

A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion.

Yin S, Gambe RG, Sun J, Martinez AZ, Cartun ZJ, Regis FFD, Wan Y, Fan J, Brooks AN, Herman SEM, Ten Hacken E, Taylor-Weiner A, Rassenti LZ, Ghia EM, Kipps TJ, Obeng EA, Cibulskis CL, Neuberg D, Campagna DR, Fleming MD, Ebert BL, Wiestner A, Leshchiner I, DeCaprio JA, Getz G, Reed R, Carrasco RD, Wu CJ, Wang L.

Cancer Cell. 2019 Feb 11;35(2):283-296.e5. doi: 10.1016/j.ccell.2018.12.013. Epub 2019 Jan 31.

25.

Rps14, Csnk1a1 and miRNA145/miRNA146a deficiency cooperate in the clinical phenotype and activation of the innate immune system in the 5q- syndrome.

Ribezzo F, Snoeren IAM, Ziegler S, Stoelben J, Olofsen PA, Henic A, Ferreira MV, Chen S, Stalmann USA, Buesche G, Hoogenboezem RM, Kramann R, Platzbecker U, Raaijmakers MHGP, Ebert BL, Schneider RK.

Leukemia. 2019 Jul;33(7):1759-1772. doi: 10.1038/s41375-018-0350-3. Epub 2019 Jan 16.

PMID:
30651631
26.

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.

Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Adès L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellström-Lindberg E, Boultwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tüchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee.

Leukemia. 2019 Jul;33(7):1747-1758. doi: 10.1038/s41375-018-0351-2. Epub 2019 Jan 11.

27.

Clonal Hematopoiesis of Indeterminate Potential.

Boettcher S, Ebert BL.

J Clin Oncol. 2019 Feb 10;37(5):419-422. doi: 10.1200/JCO.2018.79.3588. Epub 2018 Dec 27. No abstract available.

PMID:
30589599
28.

Jak-ing Up the Plaque's Lipid Core…and Even More.

Libby P, Molinaro R, Sellar RS, Ebert BL.

Circ Res. 2018 Nov 9;123(11):1180-1182. doi: 10.1161/CIRCRESAHA.118.314074. No abstract available.

29.

CHIPping Away at the Pathogenesis of Heart Failure.

Libby P, Jaiswal S, Lin AE, Ebert BL.

JAMA Cardiol. 2019 Jan 1;4(1):5-6. doi: 10.1001/jamacardio.2018.4039. No abstract available.

PMID:
30566187
30.

Inhibition of Casein Kinase 1 Alpha in Acute Myeloid Leukemia.

Ebert BL, Krönke J.

N Engl J Med. 2018 Nov 8;379(19):1873-1874. doi: 10.1056/NEJMcibr1811318. No abstract available.

PMID:
30403945
31.

Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN.

Sievers QL, Petzold G, Bunker RD, Renneville A, Słabicki M, Liddicoat BJ, Abdulrahman W, Mikkelsen T, Ebert BL, Thomä NH.

Science. 2018 Nov 2;362(6414). pii: eaat0572. doi: 10.1126/science.aat0572.

32.

CHIP (Clonal Hematopoiesis of Indeterminate Potential).

Libby P, Ebert BL.

Circulation. 2018 Aug 14;138(7):666-668. doi: 10.1161/CIRCULATIONAHA.118.034392. No abstract available.

33.

Generations of physician-scientists.

Ebert BL.

J Clin Invest. 2018 Oct 1;128(10):4208-4212. doi: 10.1172/JCI124786. Epub 2018 Oct 1. No abstract available.

34.

Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations.

Lee SC, North K, Kim E, Jang E, Obeng E, Lu SX, Liu B, Inoue D, Yoshimi A, Ki M, Yeo M, Zhang XJ, Kim MK, Cho H, Chung YR, Taylor J, Durham BH, Kim YJ, Pastore A, Monette S, Palacino J, Seiler M, Buonamici S, Smith PG, Ebert BL, Bradley RK, Abdel-Wahab O.

Cancer Cell. 2018 Aug 13;34(2):225-241.e8. doi: 10.1016/j.ccell.2018.07.003.

35.

Gli1+ Mesenchymal Stromal Cells Are a Key Driver of Bone Marrow Fibrosis and an Important Cellular Therapeutic Target.

Schneider RK, Mullally A, Dugourd A, Peisker F, Hoogenboezem R, Van Strien PMH, Bindels EM, Heckl D, Büsche G, Fleck D, Müller-Newen G, Wongboonsin J, Ventura Ferreira M, Puelles VG, Saez-Rodriguez J, Ebert BL, Humphreys BD, Kramann R.

Cell Stem Cell. 2018 Aug 2;23(2):308-309. doi: 10.1016/j.stem.2018.07.006. No abstract available.

36.

Thalidomide promotes degradation of SALL4, a transcription factor implicated in Duane Radial Ray syndrome.

Donovan KA, An J, Nowak RP, Yuan JC, Fink EC, Berry BC, Ebert BL, Fischer ES.

Elife. 2018 Aug 1;7. pii: e38430. doi: 10.7554/eLife.38430.

37.

Crbn I391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice.

Fink EC, McConkey M, Adams DN, Haldar SD, Kennedy JA, Guirguis AA, Udeshi ND, Mani DR, Chen M, Liddicoat B, Svinkina T, Nguyen AT, Carr SA, Ebert BL.

Blood. 2018 Oct 4;132(14):1535-1544. doi: 10.1182/blood-2018-05-852798. Epub 2018 Jul 31.

38.

Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity.

Sievers QL, Gasser JA, Cowley GS, Fischer ES, Ebert BL.

Blood. 2018 Sep 20;132(12):1293-1303. doi: 10.1182/blood-2018-01-821769. Epub 2018 Jul 24.

39.

Predicting progression to AML.

Sellar RS, Jaiswal S, Ebert BL.

Nat Med. 2018 Jul;24(7):904-906. doi: 10.1038/s41591-018-0114-7. No abstract available.

PMID:
29988142
40.

PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells.

Kahn JD, Miller PG, Silver AJ, Sellar RS, Bhatt S, Gibson C, McConkey M, Adams D, Mar B, Mertins P, Fereshetian S, Krug K, Zhu H, Letai A, Carr SA, Doench J, Jaiswal S, Ebert BL.

Blood. 2018 Sep 13;132(11):1095-1105. doi: 10.1182/blood-2018-05-850339. Epub 2018 Jun 28.

41.

CDK6 Antagonizes p53-Induced Responses during Tumorigenesis.

Bellutti F, Tigan AS, Nebenfuehr S, Dolezal M, Zojer M, Grausenburger R, Hartenberger S, Kollmann S, Doma E, Prchal-Murphy M, Uras IZ, Höllein A, Neuberg DS, Ebert BL, Ringler A, Mueller AC, Loizou JI, Hinds PW, Vogl C, Heller G, Kubicek S, Zuber J, Malumbres M, Farlik M, Villunger A, Kollmann K, Sexl V.

Cancer Discov. 2018 Jul;8(7):884-897. doi: 10.1158/2159-8290.CD-17-0912. Epub 2018 Jun 13.

42.

Clonal Hematopoiesis Confers Predisposition to Both Cardiovascular Disease and Cancer: A Newly Recognized Link Between Two Major Killers.

Ebert BL, Libby P.

Ann Intern Med. 2018 Jul 17;169(2):116-117. doi: 10.7326/M18-0737. Epub 2018 May 29. No abstract available.

PMID:
29809241
43.

Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.

Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, Silver AJ, Adams D, Castellano CA, Schneider RK, Padera RF, DeAngelo DJ, Wadleigh M, Steensma DP, Galinsky I, Stone RM, Genovese G, McCarroll SA, Iliadou B, Hultman C, Neuberg D, Mullally A, Wagner DD, Ebert BL.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaan8292. doi: 10.1126/scitranslmed.aan8292.

44.

Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia.

Steensma DP, Ebert BL.

N Engl J Med. 2018 Mar 29;378(13):1244-1245. doi: 10.1056/NEJMe1802610. No abstract available.

PMID:
29590545
45.

A decade of progress in myelodysplastic syndrome with chromosome 5q deletion.

List A, Ebert BL, Fenaux P.

Leukemia. 2018 Jul;32(7):1493-1499. doi: 10.1038/s41375-018-0029-9. Epub 2018 Jan 30. Review.

PMID:
29445113
46.

Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities.

Weinberg OK, Gibson CJ, Blonquist TM, Neuberg D, Pozdnyakova O, Kuo F, Ebert BL, Hasserjian RP.

Haematologica. 2018 Apr;103(4):626-633. doi: 10.3324/haematol.2017.181842. Epub 2018 Jan 11.

47.

Agonistic targeting of TLR1/TLR2 induces p38 MAPK-dependent apoptosis and NFκB-dependent differentiation of AML cells.

Eriksson M, Peña-Martínez P, Ramakrishnan R, Chapellier M, Högberg C, Glowacki G, Orsmark-Pietras C, Velasco-Hernández T, Lazarević VL, Juliusson G, Cammenga J, Mulloy JC, Richter J, Fioretos T, Ebert BL, Järås M.

Blood Adv. 2017 Oct 18;1(23):2046-2057. doi: 10.1182/bloodadvances.2017006148. eCollection 2017 Oct 24.

48.

A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.

DeAngelo DJ, Brunner AM, Werner L, Avigan D, Fathi AT, Sperling AS, Washington A, Stroopinsky D, Rosenblatt J, McMasters M, Luptakova K, Wadleigh M, Steensma DP, Hobbs GS, Attar EC, Amrein PC, Ebert BL, Stone RM, Ballen KK.

Am J Hematol. 2018 Feb;93(2):254-261. doi: 10.1002/ajh.24968. Epub 2017 Nov 21.

49.

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.

Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L, van de Loosdrecht AA, Haferlach T, Westers TM, Wells DA, Giagounidis A, Loken M, Orfao A, Lübbert M, Ganser A, Hofmann WK, Ogata K, Schanz J, Béné MC, Hoermann G, Sperr WR, Sotlar K, Bettelheim P, Stauder R, Pfeilstöcker M, Horny HP, Germing U, Greenberg P, Bennett JM.

Oncotarget. 2017 Jul 5;8(43):73483-73500. doi: 10.18632/oncotarget.19008. eCollection 2017 Sep 26.

50.

SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.

Mar BG, Chu SH, Kahn JD, Krivtsov AV, Koche R, Castellano CA, Kotlier JL, Zon RL, McConkey ME, Chabon J, Chappell R, Grauman PV, Hsieh JJ, Armstrong SA, Ebert BL.

Blood. 2017 Dec 14;130(24):2631-2641. doi: 10.1182/blood-2017-03-775569. Epub 2017 Oct 10.

Supplemental Content

Loading ...
Support Center